Idiopathic pulmonary fibrosis
Conditions
Interventions
None listed
Sponsors
Vicore Pharma AB
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Outcome results
None listed
A randomised, open-label, single-centre, drug-drug-interaction trial to evaluate the impact of carboxylesterase 2 (CES2)- and CYP3A4-inhibition on the pharmacokinetics of buloxibutid in healthy volunteers
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: Apr 29, 2026